rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.